Contents
The Hidden Dangers of MS Medications: What You Need to Know
Published: Sep 26, 2024
While oral medications for multiple sclerosis can be highly effective, they also carry risks. Understanding these potential dangers is crucial for patients and caregivers.
Infection Risks
Many MS medications work by suppressing parts of the immune system. This can leave patients more vulnerable to infections, some of which can be serious. For example, progressive multifocal leukoencephalopathy (PML) is a rare but potentially fatal brain infection associated with some MS drugs. Patients may also be at higher risk for common infections like the flu or herpes viruses.
Cardiovascular Concerns
Some oral MS medications, particularly S1PR modulators like fingolimod, can affect heart rhythm. This can cause bradycardia (slow heart rate) or irregular heartbeats, especially when first starting treatment. Patients with pre-existing heart conditions may need extra monitoring or may not be able to take certain drugs. Blood pressure changes are another potential cardiovascular effect to watch for.
Other Organ Effects
MS medications can potentially impact other organs and body systems. Liver injury is a risk with several oral drugs, requiring regular blood tests to monitor liver function. Some medications may affect lung function or vision. For example, macular edema (swelling in the retina) has been associated with fingolimod use. Regular check-ups and screening tests are important to catch any issues early.
Frequently Asked Questions
Serious side effects are generally rare, but minor side effects are more frequent.
Never stop MS medications suddenly without consulting your doctor.
Follow monitoring guidelines and report any new symptoms promptly.
Natural treatments are not necessarily safer and may lack proven efficacy.
For most patients, the benefits of treatment outweigh potential risks.
Informed Decisions
Understanding medication risks empowers patients to make informed treatment choices and stay vigilant about their health.
References
- Fragoso YD. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events. Acta Neurol Belg 2017; 117:821.
- Arvin AM, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol 2015; 72:31.
- Muñoz MA, et al. Liver injury associated with dimethyl fumarate in multiple sclerosis patients. Mult Scler 2017; :1352458516688351.
This article has been reviewed for accuracy by one of the licensed medical doctors working for Doctronic. Always discuss health information with your healthcare provider.
AI Doctor Visit Required
Appointments available 24/7
Top licensed doctors
Available in all 50 states
Full service care
Prescriptions, referrals & treatment
No insurance needed
All notes available in Doctronic
15-min consultation. No hidden costs.
AI Doctor Visit Required
Please Chat With Our AI Doctor First
Our AI doctor assessment helps our human doctors prepare for your video visit and provide better care
For safety reasons we have been forced to end this consultation.
If you believe this is a medical emergency please call 911 or your local emergency services immediately.
If you are experiencing emotional distress, please call the the Suicide & Crisis Lifeline at 988 or your local crisis services immediately.
Contact us
You can also email us at help@doctronic.ai
We aim to reply within 5-7 days
How likely are you to recommend Doctronic to friends or family?